Study #ALLIANCEA071401
ALLIANCEA071401: PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS
MD Anderson Study Status
Enrolling
Treatment Agent
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
Description
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Study phase:
Phase II
Physician name:
Carlos Kamiya Matsuoka
Department:
Neuro-Oncology
For general questions about clinical trials:
1-855-508-2908
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.